Vertex Pharmaceuticals Incorporated (VRTX)

$480.73

+1.7

(+0.35%)

Market is closed - opens 7 PM, 17 Jun 2024
star icon

Vertex Pharmaceuticals Incorporated is a biotechnology company that develops and commercializes treatments for cystic fibrosis and other serious medical conditions.

Performance

  • $478.36
    $483.53
    $480.73
    downward going graph

    0.49%

    Downside

    Day's Volatility :1.07%

    Upside

    0.58%

    downward going graph
  • $335.82
    $486.43
    $480.73
    downward going graph

    30.14%

    Downside

    52 Weeks Volatility :30.96%

    Upside

    1.17%

    downward going graph

Returns

PeriodVertex Pharmaceuticals Incorporated
3 Months
17.19%
6 Months
17.81%
1 Year
40.49%
3 Years
145.91%

Highlights

Market Capitalization
122.8B
Book Value
$71.8
Earnings Per Share (EPS)
15.41
PE Ratio
30.88
PEG Ratio
0.53
Wall Street Target Price
468.39
Profit Margin
39.46%
Operating Margin TTM
45.2%
Return On Assets TTM
12.82%
Return On Equity TTM
24.38%
Revenue TTM
10.2B
Revenue Per Share TTM
39.49
Quarterly Revenue Growth YOY
13.3%
Gross Profit TTM
5.3B
EBITDA
4.6B
Diluted Eps TTM
15.41
Quarterly Earnings Growth YOY
0.56
EPS Estimate Current Year
17.09
EPS Estimate Next Year
18.1
EPS Estimate Current Quarter
4.06
EPS Estimate Next Quarter
4.1

Analyst Recommendation

Buy
    68%Buy
    26%Hold
    5%Sell
Based on 38 Wall street analysts offering stock ratings for Vertex Pharmaceuticals Incorporated(by analysts ranked 0 to 5 stars)
Based on 38 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
26
26
26
Hold
10
10
8
Sell
2
2
2

Analyst Forecast

What analysts predicted

Downside of 2.57%

Current $480.73
Target $468.39

Company Financials

FY18Y/Y Change
Revenue
3.0B
↑ 22.46%
Net Income
2.1B
↑ 695.83%
Net Profit Margin
68.8%
↑ 58.21%
FY19Y/Y Change
Revenue
4.2B
↑ 36.59%
Net Income
1.2B
↓ 43.88%
Net Profit Margin
28.27%
↓ 40.53%
FY20Y/Y Change
Revenue
6.2B
↑ 49.07%
Net Income
2.7B
↑ 130.43%
Net Profit Margin
43.7%
↑ 15.43%
FY21Y/Y Change
Revenue
7.6B
↑ 22.06%
Net Income
2.3B
↓ 13.63%
Net Profit Margin
30.92%
↓ 12.78%
FY22Y/Y Change
Revenue
8.9B
↑ 17.91%
Net Income
3.3B
↑ 41.84%
Net Profit Margin
37.2%
↑ 6.28%
FY23Y/Y Change
Revenue
9.8B
↑ 10.17%
Net Income
3.6B
↑ 8.96%
Net Profit Margin
36.79%
↓ 0.41%
Q4 FY22Q/Q Change
Revenue
2.3B
↓ 1.35%
Net Income
818.9M
↓ 11.99%
Net Profit Margin
35.56%
↓ 4.3%
Q1 FY23Q/Q Change
Revenue
2.4B
↑ 3.13%
Net Income
699.8M
↓ 14.54%
Net Profit Margin
29.47%
↓ 6.09%
Q2 FY23Q/Q Change
Revenue
2.5B
↑ 4.99%
Net Income
915.7M
↑ 30.85%
Net Profit Margin
36.73%
↑ 7.26%
Q3 FY23Q/Q Change
Revenue
2.5B
↓ 0.39%
Net Income
1.0B
↑ 13.06%
Net Profit Margin
41.69%
↑ 4.96%
Q4 FY23Q/Q Change
Revenue
2.5B
↑ 1.38%
Net Income
968.8M
↓ 6.42%
Net Profit Margin
38.48%
↓ 3.21%
Q1 FY24Q/Q Change
Revenue
2.7B
↑ 6.73%
Net Income
1.1B
↑ 13.5%
Net Profit Margin
40.92%
↑ 2.44%
FY18Y/Y Change
Total Assets
6.2B
↑ 76.14%
Total Liabilities
1.8B
↑ 20.42%
FY19Y/Y Change
Total Assets
8.3B
↑ 33.18%
Total Liabilities
2.2B
↑ 23.34%
FY20Y/Y Change
Total Assets
11.8B
↑ 41.27%
Total Liabilities
3.1B
↑ 37.25%
FY21Y/Y Change
Total Assets
13.4B
↑ 14.3%
Total Liabilities
3.3B
↑ 8.73%
FY22Y/Y Change
Total Assets
18.2B
↑ 35.13%
Total Liabilities
4.2B
↑ 27.18%
FY23Y/Y Change
Total Assets
22.7B
↑ 25.23%
Total Liabilities
5.1B
↑ 21.51%
Q4 FY22Q/Q Change
Total Assets
18.2B
↑ 8.65%
Total Liabilities
4.2B
↑ 15.27%
Q1 FY23Q/Q Change
Total Assets
19.0B
↑ 4.54%
Total Liabilities
4.5B
↑ 7.17%
Q2 FY23Q/Q Change
Total Assets
20.3B
↑ 7.25%
Total Liabilities
4.9B
↑ 7.42%
Q3 FY23Q/Q Change
Total Assets
21.7B
↑ 6.77%
Total Liabilities
5.2B
↑ 6.85%
Q4 FY23Q/Q Change
Total Assets
22.7B
↑ 4.62%
Total Liabilities
5.1B
↓ 1.22%
Q1 FY24Q/Q Change
Total Assets
23.9B
↑ 5.22%
Total Liabilities
5.4B
↑ 4.29%
FY18Y/Y Change
Operating Cash Flow
1.3B
↑ 50.34%
Investing Cash Flow
-202.2M
↓ 53.81%
Financing Cash Flow
-71.2M
↓ 204.12%
FY19Y/Y Change
Operating Cash Flow
1.6B
↑ 23.54%
Investing Cash Flow
-1.2B
↑ 511.07%
Financing Cash Flow
126.8M
↓ 278.0%
FY20Y/Y Change
Operating Cash Flow
3.3B
↑ 107.32%
Investing Cash Flow
99.4M
↓ 108.05%
Financing Cash Flow
-505.3M
↓ 498.57%
FY21Y/Y Change
Operating Cash Flow
2.6B
↓ 18.75%
Investing Cash Flow
-340.9M
↓ 443.0%
Financing Cash Flow
-1.5B
↑ 192.51%
FY22Y/Y Change
Operating Cash Flow
4.1B
↑ 56.23%
Investing Cash Flow
-321.1M
↓ 5.81%
Financing Cash Flow
-67.7M
↓ 95.42%
Q4 FY22Q/Q Change
Operating Cash Flow
1.1B
↑ 12.86%
Investing Cash Flow
175.6M
↓ 145.71%
Financing Cash Flow
40.2M
↓ 166.78%
Q1 FY23Q/Q Change
Operating Cash Flow
899.9M
↓ 16.55%
Investing Cash Flow
-1.8B
↓ 1144.19%
Financing Cash Flow
-294.7M
↓ 833.08%
Q2 FY23Q/Q Change
Operating Cash Flow
1.1B
↑ 26.06%
Investing Cash Flow
-303.9M
↓ 83.43%
Financing Cash Flow
17.3M
↓ 105.87%

Technicals Summary

Sell

Neutral

Buy

Vertex Pharmaceuticals Incorporated is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • Capital World Investors

    9.91%
  • Vanguard Group Inc

    8.79%
  • BlackRock Inc

    8.51%
  • State Street Corporation

    4.65%
  • FMR Inc

    4.14%
  • AllianceBernstein L.P.

    2.75%

Company Information

Vertex Pharmaceuticals is an American biopharmaceutical company based in Boston, Massachusetts. It was one of the first biotech firms to use an explicit strategy of rational drug design rather than combinatorial chemistry.

Organization
Vertex Pharmaceuticals Incorporated
Employees
5400
CEO
Dr. Jeffrey Marc Leiden M.D., Ph.D.
Industry
Health Technology

FAQs